Rx Market Opportunity
Development Pipeline
Partnered Products





Partnered Products

MonoSol Rx is developing internally partnering with pharmaceutical companies to develop thin film formulations of existing prescription products and utilizing the thin film dosage to deliver new prescription products with improved efficacy. Together with development and marketing partners, targets are selected based upon technical suitability for the Company’s thin film drug delivery platform, patent expiration, patient demographics, approved indications and other factors.

For certain drugs, MonoSol Rx’s thin film drug delivery technology, when utilized for sublingual (under the tongue), buccal (in the cheek) or vaginal delivery may improve efficacy. Improved therapeutics can occur through faster onset of action or lower dosing which may also result in reduced side effects and improved safety. The potential to deliver prescription drugs with improved therapeutics is attractive to our existing and potential pharmaceutical partners.